Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Current Assets: 2020-2025

Historic Current Assets for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $328.2 million.

  • Lyell Immunopharma's Current Assets fell 27.07% to $328.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $328.2 million, marking a year-over-year decrease of 27.07%. This contributed to the annual value of $379.6 million for FY2024, which is 31.57% down from last year.
  • According to the latest figures from Q3 2025, Lyell Immunopharma's Current Assets is $328.2 million, which was up 16.30% from $282.2 million recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Current Assets peaked at $834.8 million during Q2 2021, and registered a low of $282.2 million during Q2 2025.
  • For the 3-year period, Lyell Immunopharma's Current Assets averaged around $468.7 million, with its median value being $499.8 million (2024).
  • As far as peak fluctuations go, Lyell Immunopharma's Current Assets climbed by 4.53% in 2022, and later tumbled by 43.54% in 2025.
  • Lyell Immunopharma's Current Assets (Quarterly) stood at $626.3 million in 2021, then increased by 3.99% to $651.3 million in 2022, then decreased by 14.83% to $554.7 million in 2023, then slumped by 31.57% to $379.6 million in 2024, then fell by 27.07% to $328.2 million in 2025.
  • Its last three reported values are $328.2 million in Q3 2025, $282.2 million for Q2 2025, and $309.2 million during Q1 2025.